Medtronic stock gets $110 target at TD Cowen on FDA clearance

TD Cowen reiterated a Buy rating and $110 price target for Medtronic (NYSE:MDT) after FDA clearance of its Hugo system for general surgery, expanding its U.S. market. The stock, currently at $102.88, has risen 37% in six months. Piper Sandler also upgraded MDT to Overweight, citing growth drivers. Medtronic announced a prospectus correction for its MiniMed exchange offer.

Original reporting
Published Nov 17, 2026, 1:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 2:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MDT
Bullish
medium confidence
Mentioned
$MDT
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MDTBullishMed
01

Why it matters

The FDA clearance expands Hugo’s U.S. indications by about 3.5 million additional procedures annually, which TD Cowen says materially increases the addressable market and supports further adoption.

02

Market read

Traders may reassess MDT’s growth outlook and valuation sensitivity to regulatory-driven indication expansion, reinforced by a reiterated Buy and unchanged price target.

03

What to watch

No details are provided on reimbursement, competitive dynamics in general surgery, or how quickly adoption ramps after clearance, which could temper near-term expectations.

Relevance 6/10Novelty 5/10Timing: today’s analyst reiteration and FDA-clearance catalyst

Background

Medtronic’s Hugo robotic surgery platform previously had FDA clearance for urological procedures; TD Cowen highlights new general surgery clearance.

Company-level read

Ticker impact

$MDTBullishMedium confidence
Context

TD Cowen reiterates Buy after Medtronic announced FDA clearance of its Hugo system for general surgery, expanding U.S. indications by ~3.5M procedures annually.

Expected impact

Likely upward bias as the market prices in expanded indications and sustained analyst confidence around MDT’s robotic surgery growth.

Evidence & confidence

The article ties the FDA clearance directly to a larger U.S. procedure opportunity and frames TD Cowen’s unchanged Buy/PT as a response to that incremental regulatory milestone.

Market effects

Positive read-through for medical device peers tied to robotic-assisted surgery adoption and FDA-driven indication expansion.

Primarily U.S. healthcare device demand expectations given the clearance expands U.S. procedures.

Limited direct global impact in the text, but could support broader investor sentiment toward medtech innovation and regulatory progress.

Counterpoint

The article is largely an analyst reiteration; the incremental commercial impact of the new indications may take time to translate into revenue.

Key entities

  • Medtronic, Inc.

    Medical device maker whose Hugo system received FDA clearance for general surgery, expanding indications.

  • TD Cowen

    Reiterated Buy rating and $110 price target following the FDA clearance.

  • Hugo (robotic surgery system)

    Medtronic platform whose FDA indications expanded from urology to general surgery.

Related articles

$MDTMed

Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system

Medtronic (NYSE: MDT) received FDA clearance for its Hugo™ robotic-assisted surgery system to perform general surgery procedures, including cholecystectomy and hernia repairs. The expansion covers 3.5 million annual U.S. surgeries. The system's modular design offers flexibility, and Medtronic aims to surpass 50,000 procedures globally by its fiscal year-end.

$MDTMedAI 8/10

Medtronic buys Contego Medical for $380 M, expanding access to next-generation carotid therapies

Medtronic plans to acquire Contego Medical for $380 million, expanding its carotid artery disease treatment portfolio. The deal includes Contego's FDA-approved Neuroguard IEP™ Direct System. Medtronic expects the acquisition to be minimally dilutive to adjusted EPS in FY27 and FY28, and neutral to accretive thereafter. The transaction is subject to closing conditions and expected to complete in Q3 FY25.

$MDTMedAI 9/10

Medtronic agrees to buy carotid stent maker Contego Medical for $380 million

Medtronic agreed to acquire Contego Medical for $380 million, with potential additional payments. The deal includes Contego's Neuroguard IEP Direct System and Excipio thrombectomy devices. Medtronic expects the acquisition to close in its fiscal third quarter, with minimal EPS dilution in fiscal 2027 and 2028, and a neutral to accretive effect afterward. Contego's devices focus on carotid artery disease and peripheral thrombectomy.